This requires Flash to play. Click here to download.

The information on this site is intended for health care professionals
in the United States and is not intended for the general public.

I AM A HEALTHCARE PROFESSIONAL I AM NOT A HEALTHCARE PROFESSIONAL
Zolinza® [vorinostat] capsules Reactivate Expression
Patient Product Information

Time to progression

Half of all patients (37/74) had not met progression criteria at time of analysis

4.9 months, median time to progression

  • Time to progression was measured from the time treatment began to the time the criteria for progression were first met.
  • When tumor progression was defined as a ≥25% increase in SWAT score from baseline, the estimated median time to progression in the overall patient population was 148 days (range: 1–470+ days).
  • When tumor progression was defined as a ≥25% increase in SWAT score from the nadir, the estimated median time to progression in the overall patient population was 148 days (range: 1–380 days).

Selected Important Safety Information

  • Hyperglycemia has been observed. Monitor serum glucose, especially in diabetic or potentially diabetic patients. Adjustment of diet, therapy for increased glucose, or both may be necessary to prevent hyperglycemia.

Before prescribing ZOLINZA, please read the physician Prescribing Information. The Patient Information also is available.

Back to top


ZOLINZA is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.

This site is intended only for health care professionals of the United States, its territories, and Puerto Rico.

20852912(1)-02/09-ZOL
For general information and other services for physicians
MERCK MEDICUSMERCK SOURCEMERCKServices
MerckMedicus, MerckSource, and MerckServices are trademarks of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.